Company: AEMD
Filing Date: 2025-09-05
Form Type: 424B4
Source: 0001683168-25-006701
Chunk: 37

Company: AETHLON MEDICAL INC
Filing Date: 2025-09-05
Form: 424B4
Chunk 37
---
 accompanying warrant, and after deducting
the placement agent fees and estimated offering expenses payable by us and attributing no value to the warrants sold in this offering,
purchasers of our common stock in this offering will incur immediate dilution of $0.06 per share in the net tangible book value of the
common stock they acquire. In the event that you exercise your warrants, you may experience additional dilution to the extent that the
exercise price of the warrants is higher than the tangible book value per share of our common stock. For a further description of the
dilution that investors in this offering may experience, see “Dilution.”

In addition, to the extent that
outstanding stock options or warrants, including the Inducement Warrants have been or may be exercised, outstanding restricted stock
units have been or may be settled or other shares are issued, you may experience further dilution.

We have broad discretion in the use of the net proceeds we receive from the Company Offering and may not use them effectively.

Our management will have broad
discretion in the application of the net proceeds we receive in the Company Offering, including for any of the purposes described in
the section entitled “Use of Proceeds,” and you will not have the opportunity as part of your investment
decision to assess whether our management is using the net proceeds appropriately. Because of the number and variability of factors that
will determine our use of our net proceeds from this offering, their ultimate use may vary substantially from their currently intended
use. The failure by our management to apply these funds effectively could result in financial losses that could have a material adverse
effect on our business and cause the price of our common stock to decline.

Future sales of substantial amounts of our common stock could adversely affect the market price of our common stock.

We may choose to raise additional
capital due to market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating
plans. If additional capital is raised through the sale of equity or convertible debt securities, or perceptions that those sales could
occur, the issuance of these securities could result in further dilution to investors purchasing our common stock in this offering or
result in downward pressure on the price of our common stock, and our ability to raise capital in the future.

Holders of our warrants and pre-funded warrants will have no rights as a common stockholder until they acquire our common stock.

Until you acquire shares of our
common stock upon exercise of your warrants or pre-funded warrants,